BACKGROUND: The analytical performance of multigene signatures depends on many parameters, including precision, repeatability, reproducibility and intratumor heterogeneity. Indicators such as sensitivity, specificity, positive predictive value and negative predictive value are typically used to define the clinical performance of a diagnostic test. AIM: Here we study these performance characteristics of the MammaPrint® (Agendia NV, Amsterdam, The Netherlands) 70-gene signature using the US FDA-recommended guidelines, as well as predetermined acceptance criteria. RESULTS: The clinical and analytical performance characteristics show that MammaPrint is a robust, reproducible, precise test, with a maximum variation of 5% in multiple samplings of the same tissue. CONCLUSION: MammaPrint is a reliable indicator of distant metastasis in early-stage breast cancer patients of all ages and is well suited for personalized medical care.
BACKGROUND: The analytical performance of multigene signatures depends on many parameters, including precision, repeatability, reproducibility and intratumor heterogeneity. Indicators such as sensitivity, specificity, positive predictive value and negative predictive value are typically used to define the clinical performance of a diagnostic test. AIM: Here we study these performance characteristics of the MammaPrint® (Agendia NV, Amsterdam, The Netherlands) 70-gene signature using the US FDA-recommended guidelines, as well as predetermined acceptance criteria. RESULTS: The clinical and analytical performance characteristics show that MammaPrint is a robust, reproducible, precise test, with a maximum variation of 5% in multiple samplings of the same tissue. CONCLUSION: MammaPrint is a reliable indicator of distant metastasis in early-stage breast cancerpatients of all ages and is well suited for personalized medical care.
Entities:
Keywords:
70 genes; MammaPrint®; breast cancer; molecular diagnostic test; prognosis
Authors: Mark Francis Evans; Pamela Mary Vacek; Brian Lee Sprague; Gary Stephen Stein; Janet Lee Stein; Donald Lee Weaver Journal: J Cell Biochem Date: 2019-10-08 Impact factor: 4.429
Authors: Yuan Yuan; Jin Sun Lee; Susan E Yost; Sierra Min Li; Paul H Frankel; Christopher Ruel; Daniel Schmolze; Kim Robinson; Aileen Tang; Norma Martinez; Daphne Stewart; James Waisman; Laura Kruper; Veronica Jones; Andrea Menicucci; Sahra Uygun; Erin Yoder; Bastiaan van der Baan; John H Yim; Christina Yeon; George Somlo; Joanne Mortimer Journal: Oncologist Date: 2020-11-08
Authors: Paul Baron; Peter Beitsch; Danielle Boselli; James Symanowski; James V Pellicane; Jennifer Beatty; Paul Richards; Angela Mislowsky; Charles Nash; Laura A Lee; Mary Murray; Femke A de Snoo; Lisette Stork-Sloots; Mark Gittleman; Stephanie Akbari; Pat Whitworth Journal: Ann Surg Oncol Date: 2015-12-29 Impact factor: 5.344
Authors: Inès J Beumer; Marion Persoon; Anke Witteveen; Christa Dreezen; Suet-Feung Chin; Stephen-John Sammut; Mireille Snel; Carlos Caldas; Sabine Linn; Laura J van 't Veer; Rene Bernards; Annuska M Glas Journal: Biomark Insights Date: 2016-12-11
Authors: Pat Whitworth; Peter Beitsch; Angela Mislowsky; James V Pellicane; Charles Nash; Mary Murray; Laura A Lee; Carrie L Dul; Michael Rotkis; Paul Baron; Lisette Stork-Sloots; Femke A de Snoo; Jennifer Beatty Journal: Ann Surg Oncol Date: 2016-10-21 Impact factor: 5.344
Authors: Jennifer A Crozier; Julie Barone; Pat Whitworth; Abraham Cheong; Robert Maganini; Jose Perez Tamayo; Patricia Dauer; Shiyu Wang; William Audeh; Annuska M Glas Journal: J Surg Oncol Date: 2021-12-29 Impact factor: 2.885